Stephanie M. Stanford

Stephanie M. Stanford

Auto-generated profile, based on publicly available information

Stephanie M. Stanford

Department of Medicine, University of California, San Diego, La Jolla, California, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
SSStephanie M. Stanford
Stephanie M. Stanford
NBNunzio Bottini
Nunzio Bottini

17 January 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SSStephanie M. Stanford
Stephanie M. Stanford
MMMichael F. Maestre
Michael F. Maestre
ACAmanda M. Campbell
Amanda M. Campbell
BBBeatrix Bartok
Beatrix Bartok
WKWilliam B. Kiosses
William B. Kiosses
NBNunzio Bottini
Nunzio Bottini
Objective: The fibroblast‐like synoviocytes (FLS) in the synovial intimal lining of the joint are key mediators of inflammation and joint destruction in rheumatoid arthritis (RA). In RA, these cells aggressively invade the extracellular matrix, producing cartilage‐degrading proteases and inflammatory cytokines. The behavior of FLS is controlled by multiple interconnected signal transduction pathways involving reversible phosphorylation of proteins on tyrosine residues. However, little is known about the role of the protein tyrosine phosphatases (PTPs) in FLS function. This study was undertaken to explore the expression of all of the PTP genes (the PTPome) in FLS.Methods: A comparative screening of the expression of the PTPome in FLS from patients with RA and patients with osteoarthritis (OA) was conducted. The functional effect on RA FLS of SH2 domain–containing phosphatase 2 (SHP‐2), a PTP that was up‐regulated in RA, was then analyzed by knockdown using cell‐permeable antisense oligonucleotides.Results: PTPN11 was overexpressed in RA FLS compared to OA FLS. Knockdown of PTPN11, which encodes SHP‐2, reduced the invasion, migration, adhesion, spreading, and survival of RA FLS. Additionally, signaling in response to growth factors and inflammatory cytokines was impaired by SHP‐2 knockdown. RA FLS that were deficient in SHP‐2 exhibited decreased activation of focal adhesion kinase and mitogen‐activated protein kinases.Conclusion: These findings indicate that SHP‐2 has a novel role in mediating human FLS function and suggest that it promotes the invasiveness and survival of RA FLS. Further investigation may reveal SHP‐2 to be a candidate therapeutic target for RA.

15 October 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
WHWan-Chen Hsieh
Wan-Chen Hsieh
MSMattias N.D. Svensson
Mattias N.D. Svensson
MZMartina Zoccheddu
Martina Zoccheddu
MTMichael L. Tremblay
Michael L. Tremblay
SSShimon Sakaguchi
Shimon Sakaguchi
NBNunzio Bottini
Nunzio Bottini
Loss-of-function variants of protein tyrosine phosphatase non-receptor type 2 ( PTPN2 ) enhance risk of inflammatory bowel disease and rheumatoid arthritis; however, whether the association between PTPN2 and autoimmune arthritis depends on gut inflammation is unknown. Here we demonstrate that induction of subclinical intestinal inflammation exacerbates development of autoimmune arthritis in SKG mice. Ptpn2 -haploinsufficient SKG mice — modeling human carriers of disease-associated variants of PTPN2 — displayed enhanced colitis-induced arthritis and joint accumulation of Tregs expressing RAR-related orphan receptor γT (RORγt) — a gut-enriched Treg subset that can undergo conversion into FoxP3 – IL-17 + arthritogenic exTregs. SKG colonic Tregs underwent higher conversion into arthritogenic exTregs when compared with peripheral Tregs, which was exacerbated by haploinsufficiency of Ptpn2 . Ptpn2 haploinsufficiency led to selective joint accumulation of RORγt-expressing Tregs expressing the colonic marker G protein–coupled receptor 15 (GPR15) in arthritic mice and selectively enhanced conversion of GPR15 + Tregs into exTregs in vitro and in vivo. Inducible Treg-specific haploinsufficiency of Ptpn2 enhanced colitis-induced SKG arthritis and led to specific joint accumulation of GPR15 + exTregs. Our data validate the SKG model for studies at the interface between intestinal and joint inflammation and suggest that arthritogenic variants of PTPN2 amplify the link between gut inflammation and arthritis through conversion of colonic Tregs into exTregs.

28 September 2015 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
SSStephanie M. Stanford
Stephanie M. Stanford
MSMattias N. D. Svensson
Mattias N. D. Svensson
CSCristiano Sacchetti
Cristiano Sacchetti
CPCaila A. Pilo
Caila A. Pilo
DWDennis J. Wu
Dennis J. Wu
NBNunzio Bottini
Nunzio Bottini
Objective: During rheumatoid arthritis (RA), fibroblast‐like synoviocytes (FLS) critically promote disease pathogenesis by aggressively invading the extracellular matrix of the joint. The focal adhesion kinase (FAK) signaling pathway is emerging as a contributor to the anomalous behavior of RA FLS. The receptor protein tyrosine phosphatase α (RPTPα), which is encoded by the PTPRA gene, is a key promoter of FAK signaling. The aim of this study was to investigate whether RPTPα mediates FLS aggressiveness and RA pathogenesis.Methods: Through RPTPα knockdown, we assessed FLS gene expression by quantitative polymerase chain reaction analysis and enzyme‐linked immunosorbent assay, invasion and migration by Transwell assays, survival by annexin V and propidium iodide staining, adhesion and spreading by immunofluorescence microscopy, and activation of signaling pathways by Western blotting of FLS lysates. Arthritis development was examined in RPTPα‐knockout (KO) mice using the K/BxN serum–transfer model. The contribution of radiosensitive and radioresistant cells to disease was evaluated by reciprocal bone marrow transplantation.Results: RPTPα was enriched in the RA synovial lining. RPTPα knockdown impaired RA FLS survival, spreading, migration, invasiveness, and responsiveness to platelet‐derived growth factor, tumor necrosis factor, and interleukin‐1 stimulation. These phenotypes correlated with increased phosphorylation of Src on inhibitory Y527 and decreased phosphorylation of FAK on stimulatory Y397. Treatment of RA FLS with an inhibitor of FAK phenocopied the knockdown of RPTPα. RPTPα‐KO mice were protected from arthritis development, which was due to radioresistant cells.Conclusion: By regulating the phosphorylation of Src and FAK, RPTPα mediates proinflammatory and proinvasive signaling in RA FLS, correlating with the promotion of disease in an FLS‐dependent model of RA.

29 April 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSStephanie M. Stanford
Stephanie M. Stanford
MDMichael A. Diaz
Michael A. Diaz
RARobert J. Ardecky
Robert J. Ardecky
JZJiwen Zou
Jiwen Zou
TRTarmo Roosild
Tarmo Roosild
APAnthony B. Pinkerton
Anthony B. Pinkerton

2 February 2024 in Science Advances
Verified
Journal Article
Open access
SSStephanie M. Stanford
Stephanie M. Stanford
TNTiffany P. Nguyen
Tiffany P. Nguyen
JCJoseph Chang
Joseph Chang
ZZZixuan Zhao
Zixuan Zhao
G. Lavender HackmanG. Lavender Hackman
G. Lavender Hackman
NBNunzio Bottini
Nunzio Bottini
Protein tyrosine phosphatases (PTPs) play major roles in cancer and are emerging as therapeutic targets. Recent reports suggest low–molecular weight PTP (LMPTP)—encoded by the ACP1 gene—is overexpressed in prostate tumors. We found ACP1 up-regulated in human prostate tumors and ACP1 expression inversely correlated with overall survival. Using CRISPR-Cas9–generated LMPTP knockout C4-2B and MyC-CaP cells, we identified LMPTP as a critical promoter of prostate cancer (PCa) growth and bone metastasis. Through metabolomics, we found that LMPTP promotes PCa cell glutathione synthesis by dephosphorylating glutathione synthetase on inhibitory Tyr 270 . PCa cells lacking LMPTP showed reduced glutathione, enhanced activation of eukaryotic initiation factor 2–mediated stress response, and enhanced reactive oxygen species after exposure to taxane drugs. LMPTP inhibition slowed primary and bone metastatic prostate tumor growth in mice. These findings reveal a role for LMPTP as a critical promoter of PCa growth and metastasis and validate LMPTP inhibition as a therapeutic strategy for treating PCa through sensitization to oxidative stress.